about
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis.ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapyPredictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population.Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.Assessing Heavy Metal and PCB Exposure from Tap Water by Measuring Levels in Plasma from Sporadic Breast Cancer Patients, a Pilot Study.Loss of BRCA1 expression leads to worse survival in patients with gastric carcinomaIntrafamilial disclosure of risk for hereditary breast and ovarian cancer: points to considerModulation of cyclins, p53 and mitogen-activated protein kinases signaling in breast cancer cell lines by 4-(3,4,5-trimethoxyphenoxy)benzoic acidTriple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia.Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality.Dissimilarity between sporadic, non-BRCA1/2 families and hereditary breast cancer, linked to BRCA genes, in the Tunisian population.Deleterious BRCA1/2 mutations in an urban population of Black women.Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer.Characterization of a novel germline BRCA1 splice variant, c.5332+4delA.Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer.Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krüppel-like factor 5 transcription by Sp1.Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan.Characterization of basal-like subtype in a Danish consecutive primary breast cancer cohort.Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer.Evidence of No Association Between Human Papillomavirus and Breast Cancer.Contribution of excision repair cross-complementing group 1 genotypes to triple negative breast cancer risk
P2860
Q30665329-AC067CD4-96F2-43ED-AC34-6FE2789F5C7CQ33415281-D0024BBC-E810-4685-9AC5-4162F850E08FQ33587654-47C4437E-2611-462E-8C69-DB53AFEF347AQ34256001-1E98A80B-E40A-47F4-A11B-A4216C9DF8F5Q35722508-131E8E1C-9F5E-4995-9774-A37A876CEB88Q36173170-5497EF55-C4E9-453F-846E-BF6968286EBDQ36403687-81985BA0-08FD-4CFE-9D25-1067542AAC71Q36731204-3C3E305B-C2A0-4F33-B113-7CFD744E6971Q36884609-A7315ADD-7020-4E73-AB48-7EAB46C66525Q37535523-84F82FA0-849C-47F1-8822-0582556420F6Q37652666-74C3FE50-44B0-439E-9C46-F83542A2BF43Q38806371-35EEFA54-7FDF-4B3F-BD72-3E6FCCD335DBQ39262358-4B278BF2-6989-4174-A569-2586D183C51BQ39395803-5EE04598-8704-45BF-B89A-DD6C52772E55Q40303275-B7829164-3410-421F-8D29-80E903AC3A93Q47638243-50A1BF77-88EB-43E9-9E00-90EF819DA411Q48219842-B20713CE-6B12-48F1-BF14-DFB076B1BC84Q48588785-5714FD4E-0A37-450B-A7B1-CE8D483141AAQ49269166-E8D51541-3FC7-499F-8E5A-B101F9BC2AEDQ49615943-DEAC0977-ECE4-44E1-8395-2FB2E180C55FQ49818569-E9BE8BE1-3C15-48A4-85B4-2C63FCE06C98Q50271137-05F83893-96DD-4E76-AD9B-C4ED85BE03E8Q55190068-F1CC03F7-A296-4067-BD51-FC71D1883D18Q58791244-40F7B32E-E34D-4E52-88DB-CC1D2023A27E
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
BRCA1/2 mutations and triple negative breast cancers.
@en
BRCA1/2 mutations and triple negative breast cancers.
@nl
type
label
BRCA1/2 mutations and triple negative breast cancers.
@en
BRCA1/2 mutations and triple negative breast cancers.
@nl
prefLabel
BRCA1/2 mutations and triple negative breast cancers.
@en
BRCA1/2 mutations and triple negative breast cancers.
@nl
P2860
P356
P1433
P1476
BRCA1/2 mutations and triple negative breast cancers.
@en
P2093
Beth N Peshkin
Michelle L Alabek
P2860
P356
10.3233/BD-2010-0306
P577
2010-01-01T00:00:00Z